Found: 24
Select item for more details and to access through your institution.
Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.948161
- By:
- Publication type:
- Article
Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study.
- Published in:
- Frontiers in Pharmacology, 2020, v. 11, p. N.PAG, doi. 10.3389/fphar.2020.594549
- By:
- Publication type:
- Article
OP136 A Comparison Of Health Technology Assessment Recommendations In Australia, Canada, And England: Is There Opportunity For Further Alignment?
- Published in:
- 2023
- By:
- Publication type:
- Abstract
Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement.
- Published in:
- International Journal of Technology Assessment in Health Care, 2023, v. 39, n. 1, p. 1, doi. 10.1017/S0266462323000144
- By:
- Publication type:
- Article
PD63 Impact Of Parallel Submission On The Rollout Time and Health-Technology-Assessment Recommendation Of New-Active-Substances.
- Published in:
- International Journal of Technology Assessment in Health Care, 2022, v. 38, p. S113, doi. 10.1017/S0266462322003191
- By:
- Publication type:
- Article
PD47 Associations Of Orphan Designation And Other Drug Development-Related Factors On Rollout Times And Health-Technology-Assessment Recommendations Of New-Active-Substances.
- Published in:
- International Journal of Technology Assessment in Health Care, 2022, v. 38, p. S107, doi. 10.1017/S0266462322003063
- By:
- Publication type:
- Article
Benchmarking health technology assessment agencies-methodological challenges and recommendations.
- Published in:
- 2020
- By:
- Publication type:
- journal article
PP30 Do Conditional Regulatory Pathways Affect Health Technology Assessment Recommendations?
- Published in:
- 2019
- By:
- Publication type:
- Abstract
OP172 Do Expedited Regulatory Pathways Affect Time To Health Technology Assessment Decision?
- Published in:
- 2018
- By:
- Publication type:
- Abstract
OP171 Does Parallel Regulatory-Health Technology Assessment Reviews Affect Time To Health Technology Assessment Decisions?
- Published in:
- 2018
- By:
- Publication type:
- Abstract
A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
- Published in:
- International Journal of Technology Assessment in Health Care, 2017, v. 33, n. 3, p. 350, doi. 10.1017/S0266462317000563
- By:
- Publication type:
- Article
VP155 Synchronization Of Regulatory Approval And Health Technology Assessment Recommendation Timing.
- Published in:
- 2017
- By:
- Publication type:
- Abstract
A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The Confluence of Accelerated Regulatory and Health Technology Assessment Access Pathways.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 4, p. 935, doi. 10.1002/cpt.1315
- By:
- Publication type:
- Article
The Reliability and Relevance of a Quality of Decision Making Instrument, Quality of Decision-Making Orientation Scheme (QoDoS), for Use During the Lifecycle of Medicines.
- Published in:
- Frontiers in Pharmacology, 2019, p. N.PAG, doi. 10.3389/fphar.2019.00017
- By:
- Publication type:
- Article
Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2013, v. 22, n. 9, p. 1004, doi. 10.1002/pds.3464
- By:
- Publication type:
- Article
Evaluating Quality of Decision-Making Processes in Medicines' Development, Regulatory Review and Health Technology Assessment: A Systematic Review of the Literature.
- Published in:
- Frontiers in Pharmacology, 2017, v. 8, p. 1, doi. 10.3389/fphar.2017.00189
- By:
- Publication type:
- Article
FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines.
- Published in:
- Frontiers in Pharmacology, 2017, v. 8, p. 1, doi. 10.3389/fphar.2017.00161
- By:
- Publication type:
- Article
Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.
- Published in:
- Oncologist, 2015, v. 20, n. 6, p. 683, doi. 10.1634/theoncologist.2014-0297
- By:
- Publication type:
- Article
A Process for Evaluating Quality Decision-Making Practices During the Development, Review and Reimbursement of Medicines.
- Published in:
- International Journal of Health Policy & Management, 2022, v. 11, n. 2, p. 128, doi. 10.34172/ijhpm.2020.86
- By:
- Publication type:
- Article
Evaluation of Risk-Based Approaches to the Registration of Medicines: Current Status Among African Regulatory Authorities.
- Published in:
- Pharmaceutical Medicine, 2023, v. 37, n. 3, p. 251, doi. 10.1007/s40290-023-00472-0
- By:
- Publication type:
- Article
Evaluation of the Performance of the Gulf Cooperation Council Centralised Regulatory Review Process: Strategies to Improve Product Authorisation Efficiency and Quality.
- Published in:
- Pharmaceutical Medicine, 2022, v. 36, n. 4, p. 223, doi. 10.1007/s40290-022-00432-0
- By:
- Publication type:
- Article
The Qualitative Value of Facilitated Regulatory Pathways in Europe, USA, and Japan: Benefits, Barriers to Utilization, and Suggested Solutions.
- Published in:
- Pharmaceutical Medicine, 2021, v. 35, n. 2, p. 113, doi. 10.1007/s40290-020-00372-7
- By:
- Publication type:
- Article
Standardizing the Benefit-Risk Assessment of New Medicines.
- Published in:
- Pharmaceutical Medicine, 2011, v. 25, n. 3, p. 139, doi. 10.1007/BF03256855
- By:
- Publication type:
- Article